Annual dialysis data report 2019, JSDT Renal Data Registry

Table 6 Combined usage of iron-containing phosphate binders and iron preparations (other than as phosphate binders), 2019

Iron preparations except for phosophate binders	None	Ferric citrate	Sucroferric oxyhydroxide	Concomitant use of two	Subtotal	Unspecified	No information available	Total
None	146,904	38,970	18,699	804	2,05,377	127	448	205,952
(%)	(71.5)	(19.0)	(9.1)	(0.4)	(100.0)	127	448	205,952
Oral iron agents	11,152	1,155	534	27	12,868	1	398	13,267
(%)	(86.7)	(9.0)	(4.1)	(0.2)	(100.0)	1	398	13,267
IV iron agents	42,380	3,824	2,397	124	48,725	66	2101	50,892
(%)	(87.0)	(7.8)	(4.9)	(0.3)	(100.0)	66	2101	50,892
Subtotal	200,436	43,949	21,630	955	2,66,970	194	2947	270,111
(%)	(75.1)	(16.5)	(8.1)	(0.4)	(100.0)	194	2947	270,111
Unspecified	167	40	75	3	285	854	1	1140
(%)	(58.6)	(14.0)	(26.3)	(1.1)	(100.0)	854	1	1140
No information available	607	1,526	960	40	3,133	1	58,214	61,348
(%)	(19.4)	(48.7)	(30.6)	(1.3)	(100.0)	1	58,214	61,348
Total	201,210	45,515	22,665	998	270,388	1049	61,162	332,599
(%)	(74.4)	(16.8)	(8.4)	(0.4)	(100.0)	1049	61,162	332,599

Rows represent the status of iron preparation usage; "oral iron agents" means iron-containing medications other than ferric citrate or sucroferric oxyhydroxide. Columns represent the status of iron-containing phosphate binder use, irrespective of the status of iron preparation use other than phosphate binders
^*The data were obtained from the patient survey

ISSN: 2059-1381